NCT05867147View on ClinicalTrials.gov

An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

April 26, 2023

Primary Completion Date

June 14, 2023

Study Completion Date

June 14, 2023

Conditions
Cystic Fibrosis
Interventions
DRUG

Vanzacaftor

Tablets for oral administration.

DRUG

Vanzacaftor Placebo

Placebo for oral administration.

DRUG

Moxifloxacin

Tablets for oral administration.

DRUG

Moxifloxacin Placebo

Tablets for oral administration.

Trial Locations (1)

85283

Celerion - Tempe, Tempe

All Listed Sponsors
lead

Vertex Pharmaceuticals Incorporated

INDUSTRY